Background: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) accounts for 86% of the variance between observers in the overall assessment of endoscopic severity, but has not been correlated with outcomes. Methods: Consecutive cases of acute severe colitis (ASC) defined by Truelove and Witts (TW) criteria were retrospectively evaluated. Demographic details, number of TW criteria, prior medical therapy, UCEIS and inpatient medical therapy were recorded. Pre-specified (adverse) endpoints included rescue therapy, colectomy and readmission. Results: Eighty-nine patients, 48 (54%) male, mean age 38 years, all received intravenous hydrocortisone 400 mg/d (median 5 days [range 1-11]). Median follow-up was 14 months (2-33). Forty-eight (54%) were diagnosed the year prior to or at the time of admission. Thirty-six (40%) required rescue therapy (infliximab 25/36, ciclosporin 12/36, one receiving both). Twenty-one (24%) underwent colectomy on the index admission (9/21) or during follow-up (12/21). Median UCEIS score (possible range 0-8) was 5 (3-8). UCEIS was higher in patients requiring rescue therapy or colectomy (median score 6 [range 4-8] versus 5/8 [3-8], both p < 0.005). For UCEIS ≥5, 27/54 (50%) required rescue therapy, compared with 9/33 (27%) for UCEIS ≤4 (p = 0.037). When UCEIS was ≥5, 18/54 (33%) came to colectomy during follow-up, compared with 3/33 (9%) with UCEIS ≤4. Of 14 patients with UCEIS 7 or 8, 11/14 needed rescue therapy and 13/14 met any adverse endpoint. Conclusion: Endoscopic severity is associated with a worse outcome in ASC. When the UCEIS is ≥7 on admission, almost all patients will need treatment with infliximab or ciclosporin beyond steroids. This may mark a threshold for an early decision to use infliximab or ciclosporin.
Introduction
Up to 25% patients with ulcerative colitis (UC) are hospitalized with acute severe colitis (ASC). 1 Most of these patients will respond to intravenous corticosteroids, 2 although the response rate has changed little over decades. 3 In the 30-40% of patients in whom intravenous steroid therapy fails, 1, 3 rescue therapy with monoclonal antibodies against tumour necrosis factor α or calcineurin inhibitors is often appropriate if immediate colectomy is not indicated. 4 Although overall colectomy rates in UC are falling, colectomy in ASC has remained stable over time 3, 5, 6 despite the evolution of second-line therapies for ASC. Predictors of response to corticosteroid therapy and colectomy include clinical and laboratory features such as the Truelove and Witts (TW) criteria on admission 1 or the Oxford day 3 index. 7, 8 The presence of deep ulcers at endoscopy 9 or at air enema 10 is associated with increased likelihood of colectomy in ASC. No other endoscopic score or feature has been correlated with outcomes in ASC.
Establishing accurate methods of predicting outcomes in ASC is relevant for prognostic purposes. Early identification of high-risk patients or those likely to have a poor outcome may mark a threshold for early use of rescue therapy or colectomy. Identification of a low-risk subset may allow decreased monitoring or early transition to oral therapy and discharge from hospital.
The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is the first validated index for assessing UC and accounts for 86-88% of the variance between observers in the overall assessment of endoscopic severity. 11, 12 The UCEIS is assessed at flexible sigmoidoscopy in the most severely affected area of mucosa. The score is determined by assessing mucosal vascular pattern, mucosal bleeding and erosions or ulceration and assigning the appropriate Likert scale anchor points to each descriptor, before adding them together (Table 1) . It ranges from 0 (normal) to 8 (worst colitis) and has been demonstrated accurately to predict the overall endoscopic severity across a full range of severity judged on a visual analogue scale. 11, 12 The UCEIS has yet to be correlated with outcomes in any clinical setting, although is largely unaffected by knowledge of clinical information (S. Travis et al, Submitted to JCC).
We aimed to evaluate the UCEIS in a cohort of consecutive patients, excluding tertiary referrals, presenting with ASC to a single centre in the UK to determine its association with the outcome of intensive medical therapy.
Methods

Population and Definitions
Consecutive cases of ASC admitted to the John Radcliffe Hospital between July 2010 and November 2012 were reviewed. To avoid bias from tertiary referrals only patients who were diagnosed and managed at the John Radcliffe Hospital were included. We defined ASC according to the international European Crohn's and Colitis Organisation (ECCO) consensus. 13 To ensure complete case capture, multiple databases were reviewed. Established databases of UC and inflammatory bowel disease (IBD) and all admissions to the gastroenterology ward were reviewed and cases identified based on admission and discharge information and endoscopy and pathology reports. A case for review was defined as a patient aged 18 or over who was admitted to hospital with a diagnosis of acute severe colitis.
After case identification, complete chart review was performed by two gastroenterologists (CJC and ANRF). Any discrepancies were resolved in discussion with the senior author. Inclusion criteria were age 18 or over, a confirmed diagnosis of ASC by the ECCO consensus definition 13 (i.e. those of Truelove and Witts 2 ), available data on the in-hospital clinical course, and the performance of a flexible sigmoidoscopy within 2 weeks of admission to hospital. Since this was a pragmatic study, some patients had a flexible sigmoidoscopy more than 48 hours from the time of admission, when it was considered unnecessary to repeat the scope for clinical reasons if it would not change management. An arbitrary interval of up to 2 weeks was considered clinically relevant for the whole data set, although the data were also analysed separately for those with a scope within 48 hours of admission.
We defined ASC as the passage of six or more bloody stools per day with the presence of one or more additional TW criteria (pulse >90 bpm; temperature >37.8°C; haemoglobin <105 g/L; erythrocyte sedimentation rate [ESR] >30 mm/h). Because the ESR is used less frequently than C-reactive protein (CRP) in current practice, CRP >30 mg/L was used as a surrogate; whilst unvalidated, this approach is often used and has been reported in other studies 1 and international consensus. 13 Data were collected on demographic details (gender, age) and clinical parameters (age at diagnosis, duration of disease at admission, date of admission). Medical therapy prior to admission was recorded, as well as clinical parameters on admission, including stool frequency in the 24 h preceding admission and the number of additional TW criteria (any of the criteria in additional to satisfying the stool frequency criterion were recorded as additional).
Inpatient management followed the established Oxford protocol, using intravenous hydrocortisone (400 mg), rectal hydrocortisone (200 mg), intravenous electrolytes and thromboprophylaxis with low molecular weight heparin.
14 Response was defined according to the Oxford day 3 criteria as a stool frequency of more than 8/d, or a stool frequency of 3-8/d and a CRP of more than 45 on day Table 1 . The UCEIS © is freely available for use, acknowledging that the copyright of the terminology is registered to Watson Laboratories, NJ, successors in interest to Warner Chilcott Pharmaceuticals. The score is calculated by adding the number corresponding to the appropriate Likert levels for vascular pattern, bleeding and ulceration to give a total with a range from 0 to 8. Some spots or streaks of coagulated blood on the surface of the mucosa ahead of the scope, which can be washed away Luminal mild (2) Some free liquid blood in the lumen Luminal moderate or severe (3) Frank blood in the lumen ahead of endoscope or visible oozing from mucosa after washing intra-luminal blood, or visible oozing from a haemorrhagic mucosa Erosions and ulcers None Normal mucosa, no visible erosions or ulcers Erosions (1) Tiny (≤5 mm) defects in the mucosa, of a white or yellow colour with a flat edge Superficial ulcer (2) Larger (>5 mm) defects in the mucosa, which are discrete fibrin-covered ulcers when compared with erosions, but remain superficial Deep ulcer (3) Deeper excavated defects in the mucosa, with a slightly raised edge 3 of intravenous steroids. Rescue therapy if given, followed hospital protocol (infliximab 5 mg/kg, repeated at 0, 2 and 6 weeks, or intravenous ciclosporin 2 mg/kg until response or day 4), with the choice personalized according to clinical judgement at the time. 15 Data on duration of intravenous steroid therapy and response were recorded, as well as any other inpatient medical therapy. The UCEIS has been used in Oxford since 2010 and was recorded from the flexible sigmoidoscopy related to the admission. Early intensification of infliximab therapy (administration of doses earlier than indicated in the standard induction dosing schedule as described above) was not standard protocol in this unit during this study. Outcome measures included the need for rescue therapy with ciclosporin or infliximab, colectomy or readmission. There were no deaths. The time to meeting pre-specified endpoints was collected.
Statistics
Statistical analysis was performed for pre-specified primary and secondary comparators. Analysis was performed with STATA (Version 10.0, StataCorp, TX, USA) for all analyses. Categorical or binary variables were compared using the χ 2 test. Correlations were tested using Spearman's test. Parametric variables were analysed using t-tests, and non-parametric variables were compared using the Mann-Whitney U test. A Kaplan-Meier survival analysis was performed to examine the development of endpoints by UCEIS at admission over time, with significance determined using a logrank test. Multiple logistic regression was performed to examine the binary outcomes and hypothesized predictors.
Results
Patients
Ninety-six patients fitting the inclusion criteria were identified after reviewing the included databases. Following chart review, seven cases were excluded as they were duplicates (two) or did not meet the definition of ASC (no recorded additional TW criteria). Three patients did not have a flexible sigmoidoscopy within 2 weeks of admission for ASC: one patient initially declined admission and had undergone sigmoidoscopy more than 2 weeks prior to the admission for ASC, one was admitted for elective colectomy for persistently active UC and did not have another sigmoidoscopy, and one was pregnant. Eighty-six patients (97%) underwent endoscopic evaluation within the capture period (median time to sigmoidoscopy 1 day [range 0-14]). Thirteen patients underwent sigmoidoscopy outside 48 h of admission, of whom eight had sigmoidoscopy within 72 h. All analyses were repeated, excluding the 13 patients who underwent sigmoidoscopy beyond 48 h and significant differences are reported where they occurred.
No patients were excluded because of missing or incomplete data. Dates of admission spanned the entire study period, from July 2010 to November 2012. Median follow-up from the date of admission was 13 months (range 1-28).
Demographics and clinical course
The demographic details of the population are detailed in Table 2 . Fifty-four per cent of the population were male, median age 34 years . The median disease duration prior to admission was 10 months. Fifty-four per cent of the patients had been diagnosed with UC within 1 year of their admission for ASC and 28% patients were admitted with ASC as the first presentation of UC. All patients were either established patients of the hospital or received continuing care in Oxford after admission.
Fifty-six patients (63%) met one of the pre-specified endpoints (rescue therapy, colectomy or readmission for colitis). No patients died during admission or follow-up. Of 89 patients admitted with ASC, 36 (40%) required rescue therapy; 25 patients (70%) received infliximab and 12 (33%) received ciclosporin (one patient having received sequential salvage therapies). The patient who received sequential IFX and ciclosporin did not meet any endpoint during 271 days of follow-up. No patient received tacrolimus. Colectomy was required in 21 (24%) of patients, 9 (43%) during the index admission, and 12 (57%) during follow-up. The median time to colectomy was 27 days (5-515). Readmission for colitis was required in 29 (33%) of patients, a median of 42 days (13-442) after the initial admission. Pre-specified (adverse) endpoints: rescue therapy with infliximab or ciclosporin, colectomy or readmission. There were no deaths. Ten patients who received rescue therapy (11%) subsequently underwent colectomy, 3 (3.4%) during the index admission and 7 (7.9%) during follow-up. The median time to colectomy in this group was 55 days (6-251). Eleven patients (12%) who did not receive rescue therapy underwent colectomy. The need for readmission was greater in patients requiring rescue therapy than in those who did not (44 versus 25%; p = 0.049). The median time to readmission was 42 days (13-442), and did not differ between those requiring rescue therapy and those who did not (55.5 versus 33 days; p = 0.74).
At admission all patients satisfied TW criteria defining ASC. Thirty-eight (43%) had one, 37 (42%) had two, 12 (13%) had three and 2 (2%) had all four additional TW criteria. Median stool frequency at admission was 12/d (6-25). Twenty-seven (30%) patients were naive to treatment on admission; prior therapies are listed in Table 3 . Thirty out of 48 (63%) patients with UC diagnosed at or less than 1 year prior to presentation met an adverse endpoint, compared with 26/41 (63%) who had disease for longer than 12 months (p = 0.929). Fewer patients (12/27, 44%) with no prior therapy for UC met an adverse endpoint, compared with 44/62 (70%) of patients exposed to previous therapy (p = 0.017), although this result did not retain significance when subjected to sensitivity analysis excluding patients with flexible sigmoidoscopies performed more than 48 hours after admission (46% versus 67%; p = 0.078).
UCEIS
The UCEIS close to admission (Figure 1) was variable, 66 patients (74%) scoring from 4 to 6. For two patients the UCEIS was not documented or able to be calculated from source material. These patients were excluded from analysis. As the UCEIS increased, the proportion of patients requiring rescue therapy increased from 0% with UCEIS 3 to 80% with UCEIS 8. Of 14 patients with UCEIS 7 or 8, 11 needed rescue therapy. Median UCEIS was higher in those requiring rescue therapy than those who did not (6 [4-8] versus 5 [3] [4] [5] [6] [7] [8] ; p = 0.0031). Medical rescue therapy with infliximab or ciclosporin was required in 27/54 (50%) for a UCEIS ≥5 compared with 9/33 (27%) for UCEIS ≤4 (p = 0.037). When excluding patients whose sigmoidoscopy was performed beyond 48 hours, the p value was 0.064.
Colectomy was necessary in 18/54 (33%) patients with UCEIS ≥5 compared with 3/33 (9%) with UCEIS ≤4 (p = 0.012). The median UCEIS for those patients requiring colectomy was higher than that for those who did not (6 [4-8] versus 5 [3] [4] [5] [6] [7] [8] ; p = 0.005). As UCEIS increased, the proportion of patients meeting any endpoint (rescue therapy, colectomy or readmission) increased (from 29% with UCEIS 3 to 100% with UCEIS 8). Median UCEIS was higher in those meeting any endpoint than in those not meeting an endpoint (5 [3] [4] [5] [6] [7] [8] versus 4 [3] [4] [5] [6] [7] ; p = 0.0035). Of 14 patients with UCEIS 7 or 8, 13/14 (93%) met an adverse endpoint.
A non-parametric receiver operating characteristic curve was constructed using all endpoints as the reference variable. The area under the curve was 0.69 (95% CI 0.58-0.80), representing fair diagnostic accuracy of the UCEIS in ASC. The sensitivity for predicting an endpoint at UCEIS 5 or above was only 72%, with 55% specificity. Kaplan-Meier survival analysis demonstrated significantly fewer patients meeting the endpoints over time in the UCEIS 3-5 group than in those with UCEIS greater than 5. This effect was consistent in separate analyses for colectomy, but not for readmission rates (Figure 2 ). These differences were unchanged when patients with follow-up of less than 6 months were excluded.
Multivariate analysis
The UCEIS score remained a significant predictor of requirement for rescue therapy, colectomy and all the endpoints, but not for readmission for colitis, when it was examined separately (Table 4) .
Correlation between UCEIS and TW criteria
The number of additional TW criteria did not demonstrate significant correlation with the UCEIS (Spearman's rho 0.15; p = 0.18), although the number of additional TW criteria was higher in patients who met any adverse endpoint (2 [1] [2] [3] [4] 
Discussion
The UCEIS is the first validated endoscopic scoring system for ulcerative colitis, but this is the first study to correlate the UCEIS with clinical outcomes. The decision to examine the UCEIS as a predictive measure in ASC was undertaken because of the well-defined end-points (rescue therapy, colectomy or readmission) and the short period of follow-up typically required to measure these endpoints. Clinical outcomes remain to be correlated with the UCEIS outside the setting of ASC.
Whilst this study establishes a correlation between endoscopic severity as assessed by UCEIS and clinical outcomes, it is of interest that there was no significant association between the number of additional TW criteria and the UCEIS. The number of additional TW criteria has been shown independently to predict outcomes in ASC, 1 but establishing a statistical correlation between these two indices may be difficult because of the narrow distribution and small range of additional TW criteria. The study was not powered to make such a correlation and this was not a primary outcome of interest. It is notable that some patients with biologically severe colitis as, evidenced by systemic disturbance recorded as additional TW criteria, did not have endoscopically severe disease (UCEIS >5). The UCEIS thresholds for mild, moderate and severe disease have yet to be established. Further studies with a larger sample size could better differentiate prognostic values of smaller groupings of UCEIS. Better prediction of prognosis could be tied to different therapeutic strategies, expediting rescue therapy for more unwell patients and discharge for those likely to recover.
There was no difference in endpoints between patients diagnosed within a year of presentation and those with a longer duration of disease, but patients exposed to prior therapy were significantly more likely to meet an adverse endpoint. This may represent a phenotype with a more severe disease course or medication-induced change in microflora, or reflect fewer therapeutic options in previously treated patients, making them more likely to require rescue therapy or colectomy.
The identification of UCEIS 7 or 8 as a strong predictor of need for rescue therapy may be clinically useful by representing an early threshold for using rescue therapy. Being able to identify patients at high risk of failing intravenous corticosteroid therapy on admission may help manage patient expectations or prompt physicians at non-IBD centres to transfer patients to a multidisciplinary centre where they can be monitored more closely. Early identification of high-risk patients is central to early decision-making and avoiding the risks associated with delayed colectomy. 16, 17 As the UCEIS is based on the most affected area seen at endoscopy, it is possible that by using flexible sigmoidoscopy (as opposed to complete colonoscopy) that endoscopic severity has been underestimated for some patients, but full colonoscopy in the presence of ASC is inadvisable according to ECCO guidelines. 4 The results remain significant for predicting outcomes at some levels of UCEIS.
Limitations of this study include the retrospective nature and relatively small sample size, which was not adequate to demonstrate significant correlations between some comparators. However larger cohorts of patients with ASC are typically difficult to establish and the high level of significance for our findings are not easily dismissed. Prospective validation of these findings is required. The learning curve for the UCEIS has yet to be established, so the wider applicability of this score to broader clinical practice needs further study. Further studies with larger cohorts could evaluate outcomes across less severe scores of UCEIS to allow further prognostic stratification.
Endoscopic severity measured by UCEIS is associated with a greater need for rescue therapy, colectomy and readmission in ASC. When the UCEIS is 7 or 8, 93% of patients require rescue therapy or colectomy. Establishing the UCEIS as a predictive index may assist clinicians in the difficult management decisions that frequently present in ASC. 
